Clinical Trial: A Phase Ib/II Study of DXC006 for Injection in Combination With Immune Checkpoint Inhibitors or Platinum-Based Agents for Small Cell Lung Cancer.

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07559929) titled 'A Phase Ib/II Study of DXC006 for Injection in Combination With Immune Checkpoint Inhibitors or Platinum-Based Agents for Small Cell Lung Cancer.' on April 24.

Brief Summary: This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor (ICI) or platinum-based chemotherapy in patients with small cell lung cancer (SCLC).

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Small Cell Lung Cancer

Interventi...